- Home
- AMAC vs CLLS Comparison
AMAC vs CLLS Comparison
Compare AMAC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAC | CLLS |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | Cayman Islands | France |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.7M | 394.4M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMAC | CLLS |
|---|---|---|
| Price | $9.80 | $0.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 44.2K | ★ 95.4K |
| Earning Date | N/A | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $0.88 |
| 52 Week High | $9.82 | $5.45 |
Technical Indicators
Market Signals| Indicator | AMAC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 21.48 |
| Support Level | $9.79 | N/A |
| Resistance Level | $9.81 | $2.99 |
| Average True Range (ATR) | 0.01 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 50.25 | 15.22 |
Price Performance
Historical ComparisonAbout AMAC AMR Resources Acquisition Corp Class A Ordinary Shares
AMR Resources Acquisition Corp is a newly formed blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.